Bio-Rad Laboratories vs Qiagen
Bio-Rad Laboratories reported revenue of $2.6 billion in fiscal 2025, 1.2 times Qiagen's $2.1 billion in fiscal 2025. Bio-Rad Laboratories' revenue grew 0.7% in its latest year, and Qiagen's grew 5.7%. Bio-Rad Laboratories had an operating margin of 1.8%, against 22.3% at Qiagen. Free cash flow was $375 million at Bio-Rad Laboratories and $453 million at Qiagen.
Side by side
| Bio-Rad Laboratories | Qiagen | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2.6B | $2.1B |
| Revenue growth | 0.7% | 5.7% |
| Revenue growth a year, last 5 years | 0.3% | 2.2% |
| Gross margin | 51.9% | 62.2% |
| Operating margin | 1.8% | 22.3% |
| Net margin | 29.4% | 20.3% |
| Free cash flow | $375M | $453M |
| Free cash flow margin | 14.5% | 21.7% |
| Return on capital | 0.5% | 9.9% |
| Net debt to EBITDA | −1.6x | 0.8x |
| Dividends and buybacks | $296M | $334M |
| Change in diluted share count | −3.3% | −2.6% |
| Last close | $367.50 | $49.63 |
| P/E at the last close | 9.7× | — |
| Insider trades, last 12 months | sold $1.4 million | — |
| Piotroski F-score | 5 of 9 | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Bio-Rad LaboratoriesQiagen
Operating margin
Percent of revenue
Bio-Rad LaboratoriesQiagen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Bio-Rad LaboratoriesQiagen
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Bio-Rad Laboratories and Qiagen pages.